Potentially inappropriate nursing home payments spur increased Medicare Part A, Part D oversight

Tens of millions of dollars were likely inappropriately paid to skilled nursing facilities through the Medicare Part D prescription drug program in 2006, according to a recently released report from the Department of Health and Human Services Office of the Inspector General.

According to the OIG report, Part D spent roughly $41 million that year to pay for drugs for nursing home residents who should have been covered under the Medicare Part A benefit. While admitting that a small number of facilities constituted the vast majority of inappropriate payments-30 long-term care pharmacies were responsible for 18% of the payments-investigators say that nearly every SNF and half of all pharmacies have at least one Part A patient inappropriately receiving Part D subsidized prescriptions.

In response to the oversight, the OIG made a series of recommendations to the Centers for Medicare & Medicaid Services, which include more oversight and guidance for skilled nursing facilities. Specifically, OIG told CMS to implement retrospective reviews to prevent future inappropriate payments, and to further educate facilities, pharmacies and drug plans about which Medicare plan is responsible for which medication repayment.  

More in News

Government initiatives aim to decrease number of disabled people in nursing homes

Government initiatives aim to decrease number of disabled ...

The federal government is ramping up efforts to reduce the number of disabled people in nursing homes through interagency initiatives. While many disabled people have already been moved out of ...

Nursing home optometrist faces False Claims suit alleging excessive, unreasonable eye exams ...

An optometrist in Kentucky defrauded Medicare and Medicaid by filing claims for nursing home care that was unnecessary or not provided, alleges a False Claims Act lawsuit recently brought by the federal government.

Fecal transplants to treat C. diff now need FDA approval

The Food and Drug Administration is moving to tighten regulations around fecal transplants, which research has shown to be an effective treatment for Clostridium difficile infection.